**Supplemental Digital Content 2 -Table 1.** Serum donor-specific alloantibody levels at baseline (prior to any therapy), post bortezomib treatment and post plasma exchange including the B cell Flow cytometric crossmatch channel shift and solid phase assay highest mean fluorescence index against donor HLA.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Bortezomib** | | | | | | **Control** | | | |
| **Sl no** | **BL BFXM** | **PT BFXM** | **PPE BFXM** | **BL MFI** | **PT MFI** | **PPE MFI** | **BL BFXM** | **PPE BFXM** | **BL MFI** | **PPE MFI** |
| **1\*** | **556** | **528** | **-** | **13570** | **13758** | **-** | **472** | **347** | **NA** | **NA** |
| **2** | **479** | **493** | **147** | **10764** | **10280** | **1096** | **537** | **532** | **NA** | **NA** |
| **3\*** | **573** | **622** | **-** | **8249** | **11931** | **-** | **528** | **533** | **NA** | **NA** |
| **4\*** | **642** | **619** | **-** | **16157** | **15074** | **-** | **502** | **344** | **NA** | **NA** |
| **5** | **631** | **470** | **278** | **8064** | **11843** | **6492** | **527** | **446** | **NA** | **NA** |
| **6** | **494** | **316** | **289** | **9982** | **4522** | **11351** | **472** | **401** | **NA** | **NA** |
| **7** | **487** | **404** | **342** | **12622** | **14296** | **10222** | **525** | **401** | **NA** | **NA** |
| **8** | **672** | **560** | **344** | **7894** | **8537** | **8283** | **681** | **477** | **14258** | **13365** |
| **9\*\*** | **515** | **533** | **-** | **9376** | **8820** | **-** |  |  |  |  |

\* Not Pheresed \*\* Excluded from analysis

BL – Baseline, PT – Post bortezomib treatment, PPE - Post Plasma exchange, BFXM – B cell flowcytometric crossmatch channel shift

MFI – Highest mean fluorescence index value of donor specific antibody by single antigen bead assay.

NA – Not Available.